Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454877 | 1.00 | CNR2 (0.33) | CNR2TPSAB1TPSD1TPSG1TRPV1 | |
| SCHEMBL386332 | 0.90 | CNR2 (0.33) | CNR2TPSAB1TPSD1TPSG1TRPV1 | |
| SCHEMBL386333 | 0.90 | CNR2 (0.33) | CNR2TPSAB1TPSD1TPSG1TRPV1 | |
| SCHEMBL385839 | 0.80 | MAPT (0.44) | — | |
| SCHEMBL385840 | 0.80 | MAPT (0.44) | — | |
| SCHEMBL386723 | 0.79 | TPSAB1 (0.33) | CNR2TPSAB1TPSD1TPSG1TRPV1 | |
| SCHEMBL386722 | 0.79 | TPSAB1 (0.33) | CNR2TPSAB1TPSD1TPSG1TRPV1 | |
| SCHEMBL386807 | 0.79 | TPSAB1 (0.33) | CNR2TPSAB1TPSD1TPSG1EPHX2 | |
| SCHEMBL386808 | 0.79 | TPSAB1 (0.33) | CNR2TPSAB1TPSD1TPSG1EPHX2 | |
| SCHEMBL386260 | 0.76 | DGKA (0.41) | TSHRCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | CNR2 445/4885TPSAB1 2855/4885TPSD1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.